NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
We operate a single integrated business with a direct presence in all major European, Australian and New Zealand markets with a coverage of the entire market. We have a direct presence in 12 countries and employ over 1,300 people. Our agile and adaptable infrastructure enables us to integrate and bring new transformative medicines to patients rapidly.
We combine our One Norgine expertise with country-specific focus, working closely with our local customers to understand, anticipate and respond to their needs, now and in the future.
Through our One Norgine approach, we deliver efficiencies and consistencies across our network of affiliates, while allowing them to remain empowered to maximise local opportunities.
We have a long-standing culture of collaboration. We bring a broad range of skills and resources to a partnership, including development, regulatory, market access, manufacturing and supply and commercial capabilities as well as all other functions to be successful across Europe, Australia and New Zealand combined with local experience and knowledge.
What makes us different is that we are able to structure deals in a variety of ways that can meet both Norgine’s and our partners’ strategic objectives.
We have successfully developed, manufactured and commercialised products, MOVICOL®, MOVIPREP® and PLENVU® through our infrastructure and our partners in territories where we do not have a direct sales presence.
As the ‘go to’ European specialist pharma partner of choice, we have made available a range of leading specialist products from our partners that meet critical patients’ needs in gastroenterology, hepatology, cancer and supportive care. These include: XIFAXAN®, LYMPHOSEEK®, ZIVEREL®, GELSECTAN®, FERACCRU® and SETOFILM®.
We acquire products and companies to leverage our operating infrastructure across Europe and Australia. These include: DANTRIUM®, ENDOCUFF VISION®, MUGARD®, SINTROM®, EMSELEX®, ELANTAN®, ISOKET®, DEPONIT®, SALAGEN® and ESTRADERM® which are sold across Europe and other selected markets.
Part of our strength as a partner lies in our high quality manufacturing and distribution facilities in Hengoed, Wales and Dreux, France and an external contract manufacturing network.
We are EU, US and Japan approved.
We have the capabilities to manage various manufacturing scenarios from low volume and high value to high volume and low value. We have the ability to integrate new and innovative products.
Our manufacturing site was opened in 1969.
Our key expertise are:
We produce our own products, MOVICOL®, MOVIPREP® and soon our phase III product PLENVU® for our own European, Australia and New Zealand markets and territories where our products are distributed by our partners.
Our manufacturing site was opened in Dreux in 1962.
Our key expertise are:
We produce our own products MOVICOL® READY TO TAKE, MOVICOL® liquid and products for our own European, Australia and New Zealand markets and territories where our products are distributed by our partners. In addition, we also produce products for our partners such as COLOSAN® for Vifor Pharma.
We have a strong expertise in relationship management across all technologies:
We have a long-standing expertise in developing our own products and those from our partners in Europe, the US and the rest of world.
Our efforts are focused on unmet needs in disease areas where we believe our skills and experience can make the most difference: gastroenterology, hepatology, cancer and supportive care.
Our strong in-house development team combines the expertise of clinical, regulatory, pharmacovigilance, medical affairs and scientific publications functions.
Norgine Development Centre is located in Hengoed, Wales.